Ponesimod
Small Molecule
Overview
Ponesimod is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1096146).
Patent & exclusivity (US)
Per the FDA Orange Book (10 approved US products), the latest listed US patent on Ponesimod expires 9 Oct 2042 and exclusivity 18 Mar 2026. Generic API sourcing typically opens up once these lapse.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.